Abivax SA（ABVX）资讯与事件ABVXAbivax SA

Dow Falls Nearly 300 Points, Nasdaq Rises Nearly 100 Points

The major averages were mixed near noon, with the Dow falling almost 300 points but the Nasdaq climbing nearly 100 points as oil prices eased fractionally following yesterday's sharp decline. Oil prices were slipping after Iran reportedly offered to reopen the Strait of Hormuz within seven days, while Saudi Arabia is also reportedly planning to resume its East-West pipeline as soon as this week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AutoZonereported better-than-expected Q4 EPS, with total company same-store sales rising 1.5%Shares of Quest Diagnosticsand LabCorpwere slipping after CMS announced new preliminary Medicare payment rates for lab servicesBinance is investing $100M in Circle InternetThird-party data suggested strong initial interest in Meta'sMuse, which reached the number one position on the U.S. iOS App Store in the Productivity category shortly after launchPayPalis partnering with Meta on checkouts for purchases using Muse personal agents2. WALL STREET CALLS:HSBC downgraded Netflixon viewer share loss to Alphabet'sYouTubeMetLifeupgraded to Overweight at Piper SandlerEricssondowngraded to Underweight at Morgan StanleyNorthcoast upgraded Brinkerto Buy on Chili's growthEldorado Golddouble upgraded to Buy at BofA after Gr eek site visits3. AROUND THE WEB:SoftBankis looking to issue $10B of securities and EUR 1B in debt to fund its OpenAI investment, in what would be one of the biggest junk bond sales yet, Bloomberg reportsGoldman Sachshas emerged as the lead bidder to acquire Palmer Square Capital Management, a credit manager that oversees $37B, Bloomberg saysAlibabais accelerating its vertically integrated AI strategy with the Zhenwu V900, whose larger GPU memory and bandwidth deliver roughly 3x the performance of its predecessor released just four months ago, WSJ reportsKrogerhas removed Red Bull and Boar's Head products at many stores because the company isn't accepting their price hikes, Bloomberg saysMicrosoftis cutting another 500 jobs, primarily in Xbox, as it continues restructuring and downsizing its gaming business following broader July layoffs, Business Insider reports4. MOVERS:Viking Therapeuticsgains after reporting results from its maintenance study of VK2735Grab Holdingsincreases in New York after its CEO bought $29.9M in common stockPelotonhigher after launching its foldable Peloton Tread Flex and partnering with Miley for its "Let Yourself Run" campaignAbivaxfalls in New York after appointing Rabbat as Chief Medical OfficerCelldexlower after announcing results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials5. EARNINGS/GUIDANCE:Thor Industriesreported Q4 results, with CEO Bob Martin noting the quarter was "more challenging" than expectedOn Holdingprovided guidance for Q3 and FY26MillerKnollreported Q1 results, with EPS beating consensusRoundtableannounced its outlook for Q1 and FY27Here Groupreported Q4 results, with EPS and revenue lower year-over-yearINDEXES:Near midday, the Dow was down 281.06, or 0.54%, to 51,767.77, the Nasdaq was up 78.77, or 0.29%, to 27,200.86, and the S&P 500 was down 3.94, or 0.05%, to 7,760.76.

Abivax Appoints New Chief Medical Officer and Chief Technical Officer

Fabio Cataldi, M.D., Chief Medical Officer, will be leaving Abivax in Q4. Chris Rabbat, Ph.D., who has led Global Medical Affairs since 2023, will succeed Cataldi as Chief Medical Officer, leading the medical organization as Abivax advances toward potential commercialization. Rabbat brings extensive biopharmaceutical industry experience, including deep expertise in Inflammatory Bowel Disease and experience supporting therapies through commercialization and launch. Abivax has also appointed Tim Kelly as Chief Technical Officer. Kelly will lead the company's commercial CMC, Quality and Information Technology functions, further strengthening the infrastructure supporting Abivax's continued growth and potential transition to a commercial-stage organization. Most recently, he served as Chief Technology Officer of Caribou Biosciences and previously was the CEO of Oxford Biomedica Solutions. Both executive appointments are effective immediately.

Abivax Completes Positive FDA Interaction, Plans NDA Submission by 2026

Abivax announced the successful completion of its positive pre-New Drug Application interaction with the U.S. Food and Drug Administration for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis. Constructive FDA feedback resulted in alignment on the company's planned NDA submission strategy and supported the planned content and format of the NDA submission. Abivax remains on track to submit its first NDA for obefazimod by the end of 2026.